Sakthivel Sadayappan Selected Research

Carrier Proteins (Binding Protein)

1/2022	Modulation of myosin by cardiac myosin binding protein-C peptides improves cardiac contractility in ex-vivo experimental heart failure models.
1/2021	Mutations in myosin S2 alter cardiac myosin-binding protein-C interaction in hypertrophic cardiomyopathy in a phosphorylation-dependent manner.
12/2019	Altered C10 domain in cardiac myosin binding protein-C results in hypertrophic cardiomyopathy.
1/2019	Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.
1/2019	MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy.
1/2019	Ablation of the calpain-targeted site in cardiac myosin binding protein-C is cardioprotective during ischemia-reperfusion injury.
4/2017	Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary Syndrome.
1/2016	S-glutathiolation impairs phosphoregulation and function of cardiac myosin-binding protein C in human heart failure.
11/2015	Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate.
11/2015	Cardiac muscle organization revealed in 3-D by imaging whole-mount mouse hearts using two-photon fluorescence and confocal microscopy.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sakthivel Sadayappan Research Topics

Disease

24	Heart Failure 01/2022 - 02/2009
13	Myocardial Infarction 01/2022 - 05/2010
10	Hypertrophic Cardiomyopathy (Hypertrophic Obstructive Cardiomyopathy) 01/2021 - 01/2012
9	Cardiomyopathies (Cardiomyopathy) 01/2022 - 02/2009
5	Reperfusion Injury 01/2020 - 04/2009
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 11/2017
3	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/2022 - 01/2019
3	Heart Diseases (Heart Disease) 06/2021 - 01/2014
3	Fibrosis (Cirrhosis) 02/2020 - 07/2014
3	Hypertrophy 02/2020 - 07/2012
2	Muscular Diseases (Myopathy) 01/2022 - 01/2021
2	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/2022 - 01/2012
2	Cardiac Arrhythmias (Arrythmia) 06/2021 - 01/2020
2	Inflammation (Inflammations) 12/2020 - 02/2020
2	Neoplasms (Cancer) 12/2020 - 01/2019
2	Myocardial Ischemia (Ischemic Heart Diseases) 02/2020 - 01/2012
2	Infarction (Infarctions) 01/2019 - 08/2014
2	Cardiomegaly (Heart Hypertrophy) 07/2012 - 05/2006
1	Hyperglycemia 01/2022
1	Type 2 Diabetes Mellitus (MODY) 01/2022
1	Hyperinsulinism (Hyperinsulinemia) 01/2022
1	Hyperlipidemias (Hyperlipidemia) 01/2022
1	Obesity 01/2022
1	Charcot-Marie-Tooth Disease (Peroneal Muscular Atrophy) 01/2021
1	Bethlem myopathy 01/2021
1	Limb-Girdle Muscular Dystrophies (Limb-Girdle Muscular Dystrophy) 01/2021
1	Polyneuropathies (Polyneuropathy) 01/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 01/2021
1	Arthrogryposis 01/2021
1	Cardiotoxicity 12/2020
1	Aneurysm (Aneurysms) 02/2020
1	Left Ventricular Outflow Obstruction 02/2020
1	Thrombosis (Thrombus) 02/2020
1	Ischemia 01/2019
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 12/2017
1	Acute Coronary Syndrome 04/2017
1	Infections 02/2015
1	Stroke (Strokes) 12/2014
1	Fistula 04/2013

Drug/Important Bio-Agent (IBA)

20	Carrier Proteins (Binding Protein)IBA 01/2022 - 02/2009
20	Cardiac MyosinsIBA 01/2022 - 02/2009
18	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2010
8	Biomarkers (Surrogate Marker)IBA 06/2021 - 05/2010
5	CalciumIBA 06/2021 - 01/2014
3	salicylhydroxamic acid (SHAM)IBA 01/2022 - 04/2013
3	Myosins (Myosin)IBA 01/2022 - 01/2019
3	ChromatinIBA 01/2022 - 02/2020
3	Protein Isoforms (Isoforms)IBA 12/2017 - 05/2006
2	Phosphotransferases (Kinase)IBA 01/2022 - 01/2019
2	CytokinesIBA 01/2022 - 07/2012
2	Contractile ProteinsIBA 01/2022 - 08/2007
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2020
2	ActomyosinIBA 01/2021 - 01/2019
2	Indicators and Reagents (Reagents)IBA 11/2017 - 08/2013
2	Adrenergic Agents (Adrenergic Drugs)IBA 05/2015 - 04/2013
1	Adenosine Triphosphatases (ATPase)IBA 01/2022
1	Pharmaceutical PreparationsIBA 01/2022
1	LipidsIBA 01/2022
1	Peptides (Polypeptides)IBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Serine (L-Serine)FDA Link 01/2022
1	ChemokinesIBA 01/2022
1	LipocalinsIBA 01/2022
1	phospholambanIBA 06/2021
1	Untranslated RNA (Noncoding RNA)IBA 01/2021
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2021
1	Valosin Containing ProteinIBA 01/2021
1	Monoclonal AntibodiesIBA 12/2020
1	Chymases (Chymase)IBA 02/2020
1	Histones (Histone)IBA 02/2020
1	AldosteroneIBA 01/2020
1	von Willebrand FactorIBA 01/2020
1	Eosine Yellowish-(YS) (Eosin)IBA 12/2019
1	5-ethynyl-2'-deoxyuridineIBA 01/2019
1	CalpainIBA 01/2019
1	HydrogelsIBA 01/2019
1	Staphylococcal Protein A (Protein A)IBA 01/2019
1	Small Interfering RNA (siRNA)IBA 01/2019
1	5-hydroxymethylcytosineIBA 01/2019
1	5-Methylcytosine (5 Methylcytosine)IBA 01/2019
1	Probenecid (Benemid)FDA LinkGeneric 01/2018
1	Troponin IIBA 12/2017
1	Caspase 3 (Caspase-3)IBA 12/2017
1	CateninsIBA 12/2017
1	AutoantibodiesIBA 04/2017
1	Protein Kinases (Protein Kinase)IBA 01/2016
1	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 11/2015
1	Drinking WaterIBA 12/2014
1	CollagenIBA 07/2014
1	TroponinIBA 02/2014
1	trans-crotonin (CTN)IBA 02/2014
1	CeramidesIBA 01/2014
1	Adrenergic Agonists (Adrenergic Receptor Agonist)IBA 04/2013
1	Protein Kinase CIBA 01/2013
1	IsoenzymesIBA 12/2012
1	Interleukin-10 (Interleukin 10)IBA 07/2012

Therapy/Procedure

4	Therapeutics 01/2019 - 07/2012
1	Immunotherapy 12/2020
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2020
1	Rejuvenation 01/2020